Bharat Biotech's intranasal Covid booster dose trials get DCGI nod
Date
1/29/2022 4:10:29 PM
(MENAFN- Trend News Agency)
Bharat Biotech, the maker of Covaxin, on Friday obtained approval from the Drugs Controller General of India (DCGI) for conducting trials of its intranasal booster doses against Covid-19 (BBV154), Trend reports citing The Indian EXPRESS
According to news agency ANI, the trials will be conducted at nine different sites in India.
“The Phase-3 clinical trial should be conducted as per protocol multi-centre study to compare immunogenicity and safety of BBV154 with Covaxin,” the letter issued by the DCGI said.
An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transmission.
Bharat Biotech had last month sought the drug regulator's approval to conduct phase 3 trials of the nasal vaccine. The approval comes soon after Covaxin and Serum Institute of India's Covishield were cleared for sale in the market.
MENAFN29012022000187011040ID1103611911
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.